CD274 and non-small cell lung carcinoma: Although tumoral PD-L1 can function as a marker in NSCLC,28,29 antibodies to PD-L1 alone should not be introduced as single-agent therapy for PDAC because only a few patients with mismatch repair deficiency (approximately 3%) respond to the treatment.